Motixafortide (Aphexda)
High EvidenceAn FDA-approved synthetic cyclic peptide and CXCR4 antagonist (brand name Aphexda; research name BL-8040) used together with G-CSF to mobilize blood-forming stem cells for autologous transplant in multiple myeloma. In 2026 it is being actively studied as part of combination immunotherapy for pancreatic cancer.
What It Is
Motixafortide, sold as Aphexda and known in research as BL-8040, is a synthetic cyclic 14-amino-acid peptide that blocks CXCR4, a receptor on the surface of many cells that normally anchors blood-forming (hematopoietic) stem cells inside the bone marrow. By interrupting the CXCR4/CXCL12 (SDF-1) signal that holds those cells in place, a single subcutaneous dose of motixafortide rapidly releases large numbers of stem cells into the bloodstream, where they can be collected for a transplant. On that basis the U.S. FDA approved Aphexda in September 2023, in combination with the growth factor filgrastim (G-CSF), to mobilize stem cells for collection and subsequent autologous transplantation in people with multiple myeloma. Approval was supported by the randomized, placebo-controlled Phase 3 GENESIS trial, in which adding motixafortide to G-CSF let far more patients collect enough stem cells in a single apheresis session. Motixafortide is notable as one of the relatively few synthetic peptides approved as a prescription cancer-care medicine rather than a metabolic or wellness compound — a reminder that the peptide field reaches well beyond GLP-1 weight-loss drugs. The same CXCR4 biology that frees stem cells also shapes the tumor microenvironment, so motixafortide is being investigated as an add-on to chemotherapy and immune-checkpoint drugs in hard-to-treat solid tumors. The earlier COMBAT/KEYNOTE-202 trial paired it with pembrolizumab and chemotherapy in metastatic pancreatic cancer with modest results, and in 2026 it continues to be evaluated in pancreatic cancer combinations including the MORPHEUS-PDAC umbrella study and the CheMo4METPANC trial. Important context: motixafortide is an FDA-approved prescription drug for one specific transplant use — it is not an over-the-counter peptide, not a longevity or weight-loss compound, and its cancer-treatment applications remain investigational and unproven.
Regulatory Status
Aphexda (motixafortide) was approved by the U.S. FDA in September 2023, in combination with filgrastim (G-CSF), to mobilize hematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Approval was based on the Phase 3 GENESIS trial (NCT03246529). It is not approved for any other indication; uses in solid tumors such as pancreatic cancer remain investigational.
Effective: September 2023
View FDA SourceWhy Researchers Study It
Motixafortide is studied because CXCR4 sits at the center of two important problems in medicine. First, it controls whether blood-forming stem cells stay in the bone marrow or move into the blood, so blocking it is a practical way to harvest enough stem cells for a transplant — especially in patients who mobilize poorly with standard growth factors alone. Second, the CXCR4/CXCL12 axis helps tumors hide from the immune system and resist chemotherapy, which is why researchers are testing whether adding motixafortide to checkpoint inhibitors and chemotherapy can make 'cold' tumors such as pancreatic cancer more responsive. As an FDA-approved cyclic peptide, it also serves as a real-world proof point that synthetic peptides can be developed into targeted, specialty prescription medicines far outside the metabolic/weight-loss space that dominates peptide headlines.
Proposed Mechanisms
- Selectively and reversibly blocks the CXCR4 receptor, interrupting its binding to the chemokine CXCL12 (SDF-1)
- Disrupts the CXCR4/CXCL12 anchor that retains hematopoietic stem cells in the bone marrow, driving rapid mobilization of stem cells into the peripheral blood
- Used with G-CSF (filgrastim), it increases the number of CD34+ stem cells collected per apheresis session, often in a single procedure
- In tumors, CXCR4 blockade is hypothesized to reduce immune-suppressive signaling and increase T-cell infiltration into the tumor microenvironment
- May enhance the activity of chemotherapy and immune-checkpoint inhibitors in CXCR4-driven solid tumors (investigational)
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (Phase 3, pivotal) | GENESIS trial (NCT03246529): 122 multiple-myeloma patients randomized to motixafortide + G-CSF vs placebo + G-CSF before autologous stem-cell transplant | Adding motixafortide markedly increased the proportion of patients collecting enough stem cells in fewer apheresis sessions; basis for FDA approval (Sept 2023) | Source |
| Human (Phase 2a) | COMBAT/KEYNOTE-202: motixafortide (BL-8040) + pembrolizumab + chemotherapy in metastatic pancreatic cancer | Modest signal — objective response rate 21.1% vs 16% and median overall survival 6.6 vs 6.1 months for chemotherapy context; not advanced to a randomized trial on its own | Source |
| Human (Phase I/IIb, ongoing) | MORPHEUS-PDAC umbrella study (NCT03193190): atezolizumab + motixafortide and other combinations in pretreated advanced pancreatic cancer (update reported January 2026) | Evaluating whether CXCR4 blockade plus checkpoint inhibition improves outcomes in treatment-resistant pancreatic cancer; investigational, results still emerging | Source |
| Human (Phase 2, ongoing) | CheMo4METPANC: motixafortide + the PD-1 inhibitor cemiplimab + standard chemotherapy in treatment-naïve metastatic pancreatic cancer | Reported encouraging early activity; an active example of CXCR4-antagonist combination immunotherapy in 2026 (investigational) | Source |
Commonly Discussed Benefits
Researching Motixafortide (Aphexda)? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Motixafortide (Aphexda) is a prescription oncology drug approved only for stem-cell mobilization in multiple myeloma — it is NOT an over-the-counter or research-use 'peptide' for general health
- It is not a longevity, weight-loss, recovery, or anti-aging compound, despite being a peptide
- Use in cancer treatment (e.g., pancreatic cancer) is investigational and unproven; it is given only inside clinical trials for those indications
- The label warns of serious hypersensitivity and anaphylactic reactions; doses are given with pre-medication and monitoring by a transplant/oncology team
- Can cause injection-site reactions, itching, flushing, and back pain; in people with certain leukemias it may mobilize tumor cells
- Embryo-fetal toxicity is a concern — it should not be used during pregnancy
- 'CXCR4 peptide' products sold outside the regulated pharmacy supply chain are not the same as the approved drug and are not a validated or safe way to mobilize stem cells or treat cancer
Comparisons
See how Motixafortide (Aphexda) compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Drug Trials Snapshots: Aphexda (motixafortide) — U.S. FDA PubMed
- [2] Crees et al. — Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial (Nature Medicine, 2023) PubMed
- [3] Motixafortide + pembrolizumab + chemotherapy in metastatic pancreatic cancer — COMBAT/KEYNOTE-202 (Clinical Cancer Research, 2021) PubMed
Keep researching in the app
- Log Motixafortide (Aphexda) to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Thymosin Alpha-1
High EvidenceA thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy.
SS-31
High EvidenceA mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.
Thymalin
Low EvidenceA thymic peptide preparation studied for immune system rejuvenation and age-related immune decline.
Larazotide
Medium EvidenceA synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure.
Icotrokinra (ICOTYDE)
High EvidenceThe first FDA-approved targeted oral macrocyclic peptide — an IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, marking a new era for oral peptide therapeutics.
Zilucoplan
High EvidenceA self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis.
Pegcetacoplan
High EvidenceA PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market.
Rusfertide
High EvidenceA first-in-class synthetic hepcidin-mimetic (mini-hepcidin) peptide given as a weekly subcutaneous injection to control red-blood-cell overproduction in polycythemia vera (PV). By mimicking the iron-regulating hormone hepcidin, rusfertide binds the iron exporter ferroportin and restricts iron availability, reducing the need for therapeutic phlebotomy. Developed by Protagonist Therapeutics and partnered with Takeda, it met its primary endpoint in the Phase 3 VERIFY trial and, in March 2026, received FDA acceptance of its New Drug Application with Priority Review, with a decision expected in the third quarter of 2026.